Based on the results of the AURA clinical program 15-17, osimertinib was approved worldwide to treat metastatic NSCLC patients with T790M mutation who have disease progression during or after EGFR-TKIs therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.